Jenifer Ngo Waldrop

Apr 1, 2024 | clinicalleader.com | Jenifer Ngo Waldrop |Darshan Kulkarni |Kerry Leyden |Caroline Potts

Exploring Tokenism In Clinical Trials For Rare Disease PatientsWhile recent efforts promote diversity in clinical studies, the lack of enforcement and tokenistic approaches risk leaving minorities behind. Delve into the urgency of addressing this crisis and building inclusivity for a healthier future for all.

Feb 29, 2024 | clinicalleader.com | Jenifer Ngo Waldrop

By Jenifer Ngo Waldrop, executive director, Rare Disease Diversity Coalition (RDDC) 7,000 unique diseases defined as rare, only 10% have FDA-approved treatments. For those also navigating the added hurdles of systemic discrimination and racism in healthcare, hope is often completely out of sight. Patients who find themselves at the intersection of rare diseases and marginalized populations are at critical risk, and our healthcare system is ill-equipped to support them.